Enjoy my latest creation of video clips with S/T in Spanish, in this case made with selected excerpts from a video recently published by David Sinclair.
In the description of the video is the link for those who later want to see the full original video.
This a set of clips taken from the video “David Sinclair Talks about the Future of Longevity Research; The Good & The Bad”.
New video: Dr. Aaron Cravens, CEO of Revel Pharmaceuticals at #RejuvenationStartupSummit 2022 about developing designer enzymes to treat diseases of aging, e.g. glucosepane crosslink breakers to prevent hardening of tissues such as muscle, skin, and arteries leading to increased blood pressure, vascular damage, and wrinkling of the skin.
Dr. Tobias Reichmuth, Ph.D. is Founding Partner at Maximon (https://www.maximon.com/), The Longevity Company Builder, which empowers entrepreneurs to build impactful, science-based and scalable companies providing healthy aging and rejuvenation solutions.
Maximon recently announced the launch of their 100 million CHF Longevity Co-Investment Fund, which will be looking to invest up to CHF 10 million per company, which allows them to finance up to 10–12 start-ups in this fast growing industry over the next four years.
In 2020, Dr. Reichmuth launched the Longevity Investors Conference together with Marc P. Bernegger, another Maximon Founding Partner.
Dr. Reichmuth previously founded the climate-change infrastructure fund / asset management company SUSI Partners AG, where he spent over a decade specializing in infrastructure investments in the context of energy transition (renewable energy, energy efficiency, energy storage solutions) and invested more than one billion Swiss francs.
An international team of scientists have restored the vision in blind rats using a nanoparticle-based artificial retina prosthesis that can be injected directly into the eye. The scientific advance has been successfully demonstrated for a period of eight months without the need for surgery. While it is still early days for the research, it suggests it might one day be possible to use the conjugated polymer nanoparticle (P3HT-NP) treatment in humans to correct eye problems –ranging from hereditary retinal dystrophies to the incredibly common age-related macular degeneration.
“In our ‘liquid retina device,’ P3HT nanoparticles spread out over the entire subretinal space and promoted light-dependent activation of spared inner retinal neurons, recovering subcortical, cortical and behavioral visual responses,” Fabio Benfenati, research director at the Italian Institute of Technology, told Digital Trends. “We think that P3HT-NPs provide a new avenue in retinal prosthetics.”
Retinal prostheses refer to implantable devices that are designed to help restore sight in patients with retinal degeneration. They work by introducing visual information into the retina through the electrical stimulation of surviving retinal neurons. While promising, current retinal prostheses have so far been shown to only return low-resolution vision: Useful for things like distinguishing between light and dark or recognizing simple shapes and objects. This new nanotech approach appears far more promising, offering significantly higher resolution. After just one injection, activity in the rats’ visual cortex and visual acuity were the same as those found in healthy rats.
Xenobots, a type of programmable organism made from frog cells, can replicate by spontaneously sweeping up loose stem cells, researchers say. This could have implications for regenerative medicine.
The BACE1 enzyme has a rate-limiting role in the amyloidogenic pathway (see Glossary) and has been extensively studied for its neuronal functions[1]. Since 2000, intensive efforts have focused on developing small-molecule BACE1 inhibitors to reduce amyloid β (Aβ) production in Alzheimer’s disease (AD) brains. However, human clinical trials involving most BACE1 inhibitors were stopped at Phase 2/3 due to limited therapeutic benefits[2]. BACE1 inhibitors act by reducing Aβ-related pathologies in AD brains, that is, they are used to treat the symptoms rather than the underlying disease.
Summary: Researchers engineered cells containing customized adhesion molecules that bind to specific cell partners in predictable ways to form complex multicellular entities. The discovery is a major step toward building new tissue and organs.
Source: UCSF
Researchers at UC San Francisco (UCSF) have engineered molecules that act like “cellular glue,” allowing them to direct in precise fashion how cells bond with each other. The discovery represents a major step toward building tissues and organs, a long-sought goal of regenerative medicine.
